Abstract Number: 1855 • ACR Convergence 2023
Using a Whole-population Approach to Help Design More Effective and Efficient Healthcare Services for People with Fibromyalgia
Background/Purpose: A large body of evidence has informed, internationally, management recommendations for people with fibromyalgia. However there are very few studies which have examined how…Abstract Number: 1612 • ACR Convergence 2023
Design and Validation of a Comparator for Randomized Controlled Trials of a Digital Cognitive Behavioral Therapy
Background/Purpose: The use of a control arm (comparator) in randomized controlled trials (RCTs) is considered the gold standard for trial conduct and interpretation. Choosing an…Abstract Number: 1857 • ACR Convergence 2023
More Than 50% of Rheumatoid Arthritis (RA) Patients with High or Moderate CDAI (clinical Disease Activity Index) Screen Positive on MDHAQ (multidimensional Health Assessment Questionnaire) Indices for FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen)
Background/Purpose: Treat to target in rheumatoid arthritis (RA) suggests escalation of therapy in patients whose scores are high or moderate on a disease activity index…Abstract Number: 1613 • ACR Convergence 2023
Tetrodotoxin Sensitive Nav1.7 Sodium Channel SCN9A Gene Polymorphism rs6754031(T >G) Is Associated with Fibromyalgia
Background/Purpose: SCN9A gene encodes a tetrodotoxin sensitive Nav1.7 Sodium channel expressed in dorsal root ganglia, peripheral nerves, olfactory nerves and inner ear. Rare Mutations in…Abstract Number: 2037 • ACR Convergence 2023
Assessing Risk of Depression in Common Rheumatologic Disorders Using Diagnostic Codes, Survey Scores, and Propensity Score Matching Methodology
Background/Purpose: Many studies have shown that rheumatologic conditions are associated with a higher risk of depression. The two most common methods to detect depression in…Abstract Number: 1614 • ACR Convergence 2023
Therapy Combining Millimeter Wave-based Neuromodulation with Coaching for the Improvement in Quality of Life of Patients with Fibromyalgia: A Prospective, Multicenter, Randomized, Controlled Trial
Background/Purpose: Fibromyalgia is a chronic syndrome with symptoms of moderate to severe intensity, including diffuse pain, fatigue, sleep disturbance, and cognitive impairment. While first-line recommendation…Abstract Number: PP09 • ACR Convergence 2023
Practicing Mindfulness to Improve Quality of Life
Background/Purpose: I’ve been living with symptoms of PSA and fibromyalgia for over 15 years. Four years ago, after flareup that severely impacted my mobility where…Abstract Number: 1629 • ACR Convergence 2023
Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative
Background/Purpose: Long COVID, also known as Post COVID syndrome or postacute sequelae of SARS-CoV-2 infection, refers to the development of persistent or new symptoms lasting…Abstract Number: 0328 • ACR Convergence 2023
From Patient Needs to Platform Design: Using Patient Preference to Guide the Development of a Post-Viral Fibromyalgia Management App
Background/Purpose: Post-viral fibromyalgia is a chronic condition that can develop in individuals following a viral infection, such as COVID-19. Recent studies have shown that approximately…Abstract Number: 1827 • ACR Convergence 2023
Revolutionizing Fibromyalgia Treatment: Exploring the Efficacy of a New FDA Cleared Photoceutical Device
Background/Purpose: Fibromyalgia syndrome effects 2-8% of the general population and is characterized by specific tender points. FM annual economic impact $12-$14 billion.Current treatments are only…Abstract Number: 0404 • ACR Convergence 2023
Persistent Pain and Its Predictors After Start of Anti-TNF Therapy in Rheumatoid Arthritis – Is Line of Treatment Linked to Different Pain Patterns?
Background/Purpose: Persisting pain with or without inflammation control is a common and debilitating symptom in rheumatoid arthritis (RA). Concerns have been raised that patients with…Abstract Number: 1828 • ACR Convergence 2023
Positive Screening for Fibromyalgia or Depression on Validated MDHAQ Indices Is Seen in 56-71% of Rheumatoid Arthritis Patients with High DAS28 or CDAI, 40-47% with Moderate, 2-42% with Low, and 0-21% with DAS28 or CDAI Remission
Background/Purpose: DAS28 (disease activity score 28) and CDAI (clinical disease activity index) are prominent indices to assess patients with rheumatoid arthritis (RA) quantitatively, for which…Abstract Number: 0454 • ACR Convergence 2023
Rheumatoid Arthritis Disease Activity Indices Assess More Than Inflammation: 29%-36% of Patients with Moderate or High DAS28–ESR or CDAI Have 0 or 1 Swollen Joints, but Positive Screens on MDHAQ FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen) Indices
Background/Purpose: Rheumatoid arthritis (RA) therapy is recommended to be intensified according to treat-to-target if DAS28 (disease activity score 28) or CDAI (clinical disease activity index)…Abstract Number: 1829 • ACR Convergence 2023
Blood-derived Extracellular Vesicles as Potential Diagnostic Biomarker in Fibromyalgia Syndrome
Background/Purpose: The Fibromyalgia syndrome (FMS) is a global chronic pain condition, which affects approximately 2–6% of the population. The underlying mechanism of FMS is unclear…Abstract Number: 0483 • ACR Convergence 2023
The Influence of “Fibromyalgia-ness” on Treatment Response Amongst Patients with Psoriatic Arthritis (PsA). Results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‐PsA)
Background/Purpose: Co-morbid fibromyalgia has been shown to be an important influence on non-response in patients with some inflammatory arthritides. Around 1 in 5 patients with…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 25
- Next Page »